Mass Spectrometry Innovator Bruker's Latest Launch Aids PFAS, Drug, and Contamination Detection

Drug Enforcement Tech

Posted by AI on 2025-08-26 10:06:31 | Last Updated by AI on 2025-08-26 13:11:48

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

para="When it comes to detecting contaminants, staying ahead of drug developments, and tackling the ever-present environmental pollutant crisis, innovative mass spectrometry technologies are crucial. At the American Society for Mass Spectrometry conference in Baltimore, Bruker, a key player in this field, unveiled its newest innovation, the timsMetaboTM. This benchtop mass spectrometer, with its trapped ion mobility spectrometry (TIMS) technology, delivers highly sensitive four-dimensional (4D)-metabolomics and 4D-lipidomics analysis.") Therapeutics, drugs of abuse analysis, and environmental analysis could all benefit from it.

Brukers senior vice president, Jeffrey Zonderman, explained how this innovation, along with the companys direct real-time mass spectrometry (DART-MS) technology, integrates RECIPE Chemicals + Instruments ClinMass for LCMS and the upcoming ClinDART assay kits, which will both operate on the EVOQ DART-TQ+ system.

According to Zonderman, these advancements will have a significant impact on the field of small molecule analysis, which is critical for addressing pressing environmental and public health issues. He stated that the increased sensitivity and capabilities of the timsMetabo will allow researchers to tackle more complex assays and challenges in contaminant analysis, such as wastewater analysis and per- and polyfluoroalkyl substances (PFAS) analysis.

This is especially important because, as Zonderman noted, TIMS can separate and identify analytes based on their shape and orientation, giving researchers unprecedented separation and selectivity power. This level of resolution is especially useful for detecting contaminants in complicated mixtures like wastewater or soil samples, where thousands of PFAS analogs may be present.

In addition, Brukers majority investment in RECIPE Chemicals + Instruments GmbH, a European provider of therapeutic drug monitoring and clinical diagnostic kits, is expected to expand its capabilities in the field of therapeutic drug monitoring and drugs of abuse screening.

Looking to the future, Zonderman believes that these innovations are ushering in an exciting time for the sector, with chromatography-free mass spectrometry systems like DART and TIMS becoming more and more accessible, and with it, mass spectrometry itself becoming more accessible to a wider range of experts and transitioning from being solely an expert-only domain.

He emphasized that chromatography-free systems are the way of the future and that uptake on these systems has been significant, with customers and collaborators proving the efficacy of these approaches at this year's ASMS conference.

In conclusion, Brukers newest mass spectrometry innovations hold promise for tackling the ever-growing challenges of drug monitoring, contamination detection, and environmental analysis, and the field of small molecule analysis is poised for an exciting future.

This development underscores the importance of mass spectrometry in addressing critical public health and environmental challenges and expanding accessibility to mass spectrometry across a wider range of experts.

This article was written as a factual representation of the provided information without editorializing or adding personal opinions. Let me know if this article suits your needs.

Go!